A California-based biotech company is finding early success on Tuesday after the company announced positive preliminary data of Vebreltinib in patients with non-CNS met fusion...

To read the full story on AllPennyStocks.com, click here.

Grafico Azioni Apollomics (NASDAQ:APLMW)
Storico
Da Gen 2025 a Feb 2025 Clicca qui per i Grafici di Apollomics
Grafico Azioni Apollomics (NASDAQ:APLMW)
Storico
Da Feb 2024 a Feb 2025 Clicca qui per i Grafici di Apollomics